Blopress AG Share Tops 60% in Generic Market, Aims for Further Growth: ASKA President Yamaguchi

ASKA President Takashi Yamaguchi ASKA Pharmaceutical President Takashi Yamaguchi reckons that around 20% of the market share for Takeda Pharmaceutical’s hypertension drug Blopress (candesartan) was taken over by its generic versions, and its authorized generic (AG) version has obtained a...read more